Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment: a Multicenter Randomized Controlled Trial

NCT06159283 is registered in ClinicalTrials.gov with Jaehoon Ko as lead sponsor.

NCT NCT06159283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06159283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment: a Multicenter Randomized Controlled Trial
Lead sponsor
Jaehoon Ko
Phase
Phase 2
Overall status
Unknown status
Start date
March 18, 2024
Completion date
December 31, 2025
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19